Imbruvica (ibrutinib) is a targeted therapy used to treat various types of blood cancers by inhibiting the protein Bruton’s tyrosine kinase (BTK), which allows for the growth and survival of cancer cells. Imbruvica is a long-term therapy prescribed once daily, and patients may continue treatment as long as they respond well. The capsules should be taken orally and are available in different dosages depending on the type of cancer being treated. Side effects may include nausea and bleeding, and patients should inform their doctor of any other medications they are taking to avoid drug interactions. Imbruvica should not be taken if a patient is allergic to the drug or is pregnant or breastfeeding. Patients should seek the guidance of their healthcare provider before taking Imbruvica.